Understanding the differences between two types of mutations in a protein linked to blood cancers.
Official title: The Pathophysiology of Type 1 Versus Type 2 Mutant Calreticulin-Drivenmyeloproliferative Neoplasms
Funded at University of Utah · NIH-11158469 · Data updated 2026-11-12
This study is looking at how different mutations in a protein called calreticulin affect the progression of myeloproliferative neoplasms (MPNs) and aims to find new treatments, inviting patients with MPNs to help by participating in genetic testing and check-ups.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Utah NIH-funded |
| Lab location | 1 site (Salt Lake City, United States) |
| Project start | August 1, 2024 |
| Project end | August 31, 2027 |
| Funding year | 2024 |
| Award (this year) | $422,510 |
| NIH project number | 7R01HL165119-03 |
| Project ID | NIH-11158469 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for participation are individuals diagnosed with myeloproliferative neoplasms, particularly those with calreticulin mutations.
✕Less likely to help
Patients without myeloproliferative neoplasms or those with different underlying genetic causes may not benefit from this research.
What this research studies
This research investigates the pathophysiology of myeloproliferative neoplasms (MPNs), specifically focusing on the differences between type 1 and type 2 mutations in the calreticulin protein. By examining how these mutations affect disease progression and patient outcomes, the study aims to identify potential new therapies that could more effectively treat these conditions. The approach includes analyzing the genetic and molecular mechanisms behind these mutations and their impact on signaling pathways involved in blood cell production. Patients with MPNs may have the opportunity to contribute to this research through genetic testing and clinical assessments.
Why it matters
Potential benefit: If successful, this research could lead to the development of targeted therapies that improve treatment outcomes for patients with myeloproliferative neoplasms.
How similar studies have gone: Previous research has shown promising results in understanding the role of genetic mutations in blood cancers, suggesting that this approach could yield valuable insights.
Where this research is happening
-
University of Utah
Salt Lake City, United States Active
Researchers
- Principal investigator: Elf, Shannon Elisabeth — University of Utah
- Study coordinator: Elf, Shannon Elisabeth
Related research
Other NIH-funded projects on the same topics.
-
Biomarker clues to catch pancreatic cancer early in cysts
A study from UC San Diego is testing blood and cyst-fluid markers to help tell high-risk pancreatic cysts from low-risk ones so that people with pancreatic cysts can get the right care sooner.
-
Myeloproliferative Neoplasm Research Consortium
A large research collaboration across multiple centers aims to improve survival for patients with myelofibrosis and related myeloproliferative neoplasms through coordinated laboratory, translational, and clinical work.
-
Understanding how different CALR mutations drive certain blood cancers
This grant explores how two CALR mutation types cause myeloproliferative neoplasms and could lead to better treatments for people with these blood cancers.
-
Cell Competition in Myeloproliferative Neoplasms
This NIH grant explores how healthy and mutant blood stem cells interact in certain blood cancers to understand why some patients progress and how future therapies might help.
-
Targeting ERK’s brake pedals to slow cancer progression
Aims to block the parts of ERK signaling that speed up cancer progression, by guiding drugs to the substrate-binding domains that act like accelerator pedals in myeloproliferative neoplasms and related cancers.
-
Biomarker work to predict pancreatic IPMN cancer risk
A Duke University researcher is testing biomarkers to tell which pancreatic IPMN cysts are likely to become invasive cancer.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.